The controversy around Palantir is not that it has no business at all, but rather how high the market’s expectations are for it. Even if demand for AI solutions is strong, the risk-reward ratio for $PLTRB may still not be attractive enough, because the premium valuation requires the company to sustain very rapid growth for many years and to convert demand into stable profits. Once the rate at which contracts are signed slows down, or if the process for enterprise customers to move from trials to large-scale purchases takes longer than expected, the degree of valuation compression could be greater than the decline in performance itself. Many investors focus only on revenue growth rate, but overlook how the purchase price determines the margin of error. Palantir may be an excellent company, but an excellent company does not mean it is worth buying at any price. What should be done now is to break down order quality, the sustainability of commercialization, and cash flow—not simply follow along with an AI label.

#AI投资 #US stock valuation